June 2024—Leica Biosystems announced that its flagship digital pathology system, Aperio GT 450 DX, has received 510(k) clearance from the U.S. Food and Drug Administration. The Aperio GT 450 DX is proven technology that offers both SVS and Native DICOM and consistently delivers high-quality images at a turnaround time of less than 32 seconds per slide.
Leica Biosystems has 25 years of experience implementing, integrating, and innovating in the digital pathology space, enabling clinicians to advance their cancer diagnoses and improve lives.
“Digital pathology is rapidly emerging as the cornerstone of modern health care, revolutionizing the field of pathology as laboratories across the globe embrace this transformative technology,” says Dr. Sony Wirio, regional chief pathologist and director of pathology informatics at Kaiser Permanente, Southern California. “Drawing from our extensive experience in implementing digital pathology within our group of over 100 pathologists, we are excited to be a part of this groundbreaking shift that is shaping digital diagnostics and enhancing patient outcomes.”
“There is no better time for laboratories to optimize their workflow with digital,” says Naveen Chandra, vice president and general manager of digital pathology at Leica Biosystems. “Today, clinicians are faced with having to do more with less—digital pathology enables them to maintain a high standard of quality with world-class images and a fast turnaround time, for the best patient care possible.”
Leica Biosystems Corporate Communications
Lauren Meinhardt
Lauren.meinhardt@leicabiosystems.com
657-226-6970